Padmini Komalavilas
Last active: 3/11/2015

  1. Brilliant blue FCF is a nontoxic dye for saphenous vein graft marking that abrogates response to injury. Hocking KM, Luo W, Li FD, Komalavilas P, Brophy C, Cheung-Flynn J (2016) J Vasc Surg 64(1): 210-8
    › Citation · 25704409 (PubMed) · PMC4544660 (PubMed Central)
  2. Surgical vein graft preparation promotes cellular dysfunction, oxidative stress, and intimal hyperplasia in human saphenous vein. Osgood MJ, Hocking KM, Voskresensky IV, Li FD, Komalavilas P, Cheung-Flynn J, Brophy CM (2014) J Vasc Surg 60(1): 202-11
    › Citation · 23911244 (PubMed) · PMC3926896 (PubMed Central)
  3. Pressure control during preparation of saphenous veins. Li FD, Eagle S, Brophy C, Hocking KM, Osgood M, Komalavilas P, Cheung-Flynn J (2014) JAMA Surg 149(7): 655-62
    › Citation · 24759942 (PubMed) · PMC4102634 (PubMed Central)
  4. Brilliant blue FCF as an alternative dye for saphenous vein graft marking: effect on conduit function. Voskresensky IV, Wise ES, Hocking KM, Li FD, Osgood MJ, Komalavilas P, Brophy C, Cheung-Flynn J (2014) JAMA Surg 149(11): 1176-81
    › Citation · 25251505 (PubMed) · PMC4237645 (PubMed Central)
  5. Role of cyclic nucleotide-dependent actin cytoskeletal dynamics:Ca(2+)](i) and force suppression in forskolin-pretreated porcine coronary arteries. Hocking KM, Baudenbacher FJ, Putumbaka G, Venkatraman S, Cheung-Flynn J, Brophy CM, Komalavilas P (2013) PLoS One 8(4): e60986
    › Citation · 23593369 (PubMed) · PMC3625185 (PubMed Central)
  6. Intimal thickness associated with endothelial dysfunction in human vein grafts. Li FD, Sexton KW, Hocking KM, Osgood MJ, Eagle S, Cheung-Flynn J, Brophy CM, Komalavilas P (2013) J Surg Res 180(1): e55-62
    › Citation · 22763213 (PubMed) · PMC3515722 (PubMed Central)
  7. Cell-permeant peptide inhibitors of vasospasm and intimal hyperplasia. Osgood MJ, Flynn CR, Komalavilas P, Brophy C (2013) Vascular 21(1): 46-53
    › Citation · 23104826 (PubMed) · PMC4180429 (PubMed Central)
  8. Role of the renin-angiotensin system in the pathogenesis of intimal hyperplasia: therapeutic potential for prevention of vein graft failure? Osgood MJ, Harrison DG, Sexton KW, Hocking KM, Voskresensky IV, Komalavilas P, Cheung-Flynn J, Guzman RJ, Brophy CM (2012) Ann Vasc Surg 26(8): 1130-44
    › Citation · 22445245 (PubMed) · PMC4189806 (PubMed Central)
  9. Inhibition of Mitogen Activated Protein Kinase Activated Protein Kinase II with MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. Muto A, Panitch A, Kim N, Park K, Komalavilas P, Brophy CM, Dardik A (2012) Vascul Pharmacol 56(1-2): 47-55
    › Citation · 22024359 (PubMed) · PMC3268886 (PubMed Central)
  10. Surgical skin markers impair human saphenous vein graft smooth muscle and endothelial function. Eagle S, Brophy CM, Komalavilas P, Hocking K, Putumbaka G, Osgood M, Sexton K, Leacche M, Cheung-Flynn J (2011) Am Surg 77(7): 922-8
    › Citation · 21944360 (PubMed) · PMC3957273 (PubMed Central)